Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

ImmunoGen

DB:IMU
Snowflake Description

Reasonable growth potential with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
IMU
DB
$596M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The last earnings update was 25 days ago. More info.


Add to Portfolio Compare Print
  • ImmunoGen has significant price volatility in the past 3 months.
IMU Share Price and Events
7 Day Returns
-10.6%
DB:IMU
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
22.7%
DB:IMU
-13.2%
DE Biotechs
-20.9%
DE Market
IMU Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
ImmunoGen (IMU) -10.6% -21.6% -25.5% 22.7% 3.4% -66.6%
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • IMU outperformed the Biotechs industry which returned -13.2% over the past year.
  • IMU outperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
IMU
Industry
5yr Volatility vs Market
Related Companies

IMU Value

 Is ImmunoGen undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of ImmunoGen to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for ImmunoGen.

DB:IMU Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 10 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.9%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:IMU
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.19
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.188 (1 + (1- 21%) (4.5%))
1.154
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.15
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.154 * 5.44%)
5.89%

Discounted Cash Flow Calculation for DB:IMU using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for ImmunoGen is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:IMU DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 5.89%)
2020 -99.45 Analyst x2 -93.92
2021 -132.61 Analyst x2 -118.27
2022 -104.80 Analyst x2 -88.27
2023 60.00 Analyst x1 47.73
2024 90.32 Analyst x2 67.84
2025 113.62 Est @ 25.8% 80.60
2026 134.01 Est @ 17.95% 89.78
2027 150.69 Est @ 12.45% 95.34
2028 163.64 Est @ 8.59% 97.78
2029 173.30 Est @ 5.9% 97.79
Present value of next 10 years cash flows $276.00
DB:IMU DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $173.30 × (1 + -0.39%) ÷ (5.89% – -0.39%)
$2,749.22
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $2,749.22 ÷ (1 + 5.89%)10
$1,551.34
DB:IMU Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $276.00 + $1,551.34
$1,827.34
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1,827.34 / 174.32
$10.48
DB:IMU Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:IMU represents 0.89722x of NasdaqGS:IMGN
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.89722x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 10.48 x 0.89722
€9.41
Value per share (EUR) From above. €9.41
Current discount Discount to share price of €3.07
= -1 x (€3.07 - €9.41) / €9.41
67.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price ImmunoGen is available for.
Intrinsic value
>50%
Share price is €3.07 vs Future cash flow value of €9.41
Current Discount Checks
For ImmunoGen to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • ImmunoGen's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • ImmunoGen's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for ImmunoGen's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are ImmunoGen's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:IMU PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-0.70
NasdaqGS:IMGN Share Price ** NasdaqGS (2020-04-03) in USD $3.42
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of ImmunoGen.

DB:IMU PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:IMGN Share Price ÷ EPS (both in USD)

= 3.42 ÷ -0.70

-4.87x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ImmunoGen is loss making, we can't compare its value to the Europe Biotechs industry average.
  • ImmunoGen is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does ImmunoGen's expected growth come at a high price?
Raw Data
DB:IMU PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.87x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 10 Analysts
15.9%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for ImmunoGen, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on ImmunoGen's assets?
Raw Data
DB:IMU PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $-0.51
NasdaqGS:IMGN Share Price * NasdaqGS (2020-04-03) in USD $3.42
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:IMU PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:IMGN Share Price ÷ Book Value per Share (both in USD)

= 3.42 ÷ -0.51

-6.75x

* Primary Listing of ImmunoGen.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ImmunoGen has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.
X
Value checks
We assess ImmunoGen's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. ImmunoGen has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

IMU Future Performance

 How is ImmunoGen expected to perform in the next 1 to 3 years based on estimates from 10 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
15.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is ImmunoGen expected to grow at an attractive rate?
  • ImmunoGen's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • ImmunoGen's earnings growth is expected to exceed the Germany market average.
  • ImmunoGen's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:IMU Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:IMU Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 10 Analysts 15.9%
DB:IMU Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 10 Analysts 25.6%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:IMU Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:IMU Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 262 96 18 6
2023-12-31 123 -22 -80 7
2022-12-31 59 -99 -135 8
2021-12-31 43 -98 -135 10
2020-12-31 61 -94 -106 10
2020-04-05
DB:IMU Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 82 -88 -104
2019-09-30 51 -97 -151
2019-06-30 48 -102 -176
2019-03-31 42 -106 -174
2018-12-31 53 -166 -169
2018-09-30 79 -155 -140
2018-06-30 77 -69 -150
2018-03-31 107 -9 -117
2017-12-31 115 8 -96
2017-09-30 90 1 -117
2017-06-30 89 -93 -105
2017-03-31 57 -150 -142

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • ImmunoGen's earnings are expected to grow by 15.9% yearly, however this is not considered high growth (20% yearly).
  • ImmunoGen's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:IMU Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below

All data from ImmunoGen Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:IMU Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 0.23 0.82 -0.38 6.00
2023-12-31 -0.36 0.18 -0.63 7.00
2022-12-31 -0.64 -0.18 -1.04 8.00
2021-12-31 -0.72 -0.41 -1.02 10.00
2020-12-31 -0.64 -0.41 -0.80 10.00
2020-04-05
DB:IMU Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -0.70
2019-09-30 -1.02
2019-06-30 -1.19
2019-03-31 -1.21
2018-12-31 -1.21
2018-09-30 -1.04
2018-06-30 -1.24
2018-03-31 -1.08
2017-12-31 -0.98
2017-09-30 -1.32
2017-06-30 -1.21
2017-03-31 -1.63

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if ImmunoGen will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess ImmunoGen's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
ImmunoGen has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

IMU Past Performance

  How has ImmunoGen performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare ImmunoGen's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • ImmunoGen does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare ImmunoGen's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare ImmunoGen's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
ImmunoGen's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from ImmunoGen Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:IMU Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 82.27 -104.13 38.49
2019-09-30 50.82 -150.75 38.44
2019-06-30 48.47 -175.80 37.58
2019-03-31 42.22 -173.98 37.53
2018-12-31 53.45 -168.84 36.75
2018-09-30 79.48 -140.16 36.04
2018-06-30 77.03 -150.04 35.60
2018-03-31 106.76 -117.28 35.79
2017-12-31 115.45 -96.01 33.91
2017-09-30 89.85 -117.05 33.40
2017-06-30 89.03 -105.10 34.95
2017-03-31 57.41 -142.15 35.41
2016-12-31 48.63 -156.73 38.53
2016-09-30 52.81 -155.81 38.05
2016-06-30 60.00 -144.82 33.62
2016-03-31 65.21 -129.37 34.88
2015-12-31 56.92 -119.06 30.64
2015-09-30 87.19 -72.20 29.46
2015-06-30 85.54 -60.74 28.23
2015-03-31 78.67 -56.76 27.42
2014-12-31 74.12 -72.60 26.46
2014-09-30 55.88 -82.42 25.04
2014-06-30 59.90 -71.36 24.47
2014-03-31 57.98 -66.74 23.39
2013-12-31 76.11 -30.64 22.34
2013-09-30 48.66 -58.85 22.36
2013-06-30 35.54 -72.81 21.47

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if ImmunoGen has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if ImmunoGen has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if ImmunoGen improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess ImmunoGen's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
ImmunoGen has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

IMU Health

 How is ImmunoGen's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up ImmunoGen's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • ImmunoGen is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • ImmunoGen's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of ImmunoGen's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • ImmunoGen has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from ImmunoGen Company Filings, last reported 3 months ago.

DB:IMU Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 -76.12 2.08 176.23
2019-09-30 -86.23 2.08 204.49
2019-06-30 -68.17 2.07 239.83
2019-03-31 -27.60 2.07 270.40
2018-12-31 10.97 2.06 262.25
2018-09-30 46.89 2.06 303.21
2018-06-30 89.19 2.06 345.06
2018-03-31 -36.31 2.05 218.38
2017-12-31 -17.90 2.05 267.11
2017-09-30 -111.30 3.02 194.85
2017-06-30 -173.23 97.30 150.34
2017-03-31 -167.53 97.13 126.57
2016-12-31 -152.85 96.97 159.96
2016-09-30 -122.54 96.79 196.00
2016-06-30 -82.30 96.63 245.03
2016-03-31 -41.14 0.00 182.91
2015-12-31 -16.69 0.00 212.28
2015-09-30 11.61 0.00 247.84
2015-06-30 35.10 0.00 278.11
2015-03-31 59.67 0.00 111.83
2014-12-31 77.47 0.00 106.60
2014-09-30 58.97 0.00 121.80
2014-06-30 75.70 0.00 142.26
2014-03-31 97.93 0.00 164.08
2013-12-31 130.04 0.00 178.09
2013-09-30 119.44 0.00 174.84
2013-06-30 121.85 0.00 194.96
  • ImmunoGen has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if ImmunoGen's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • ImmunoGen has sufficient cash runway for 1.9 years based on current free cash flow.
  • ImmunoGen has sufficient cash runway for 1.6 years if free cash flow continues to grow at historical rates of 8.3% each year.
X
Financial health checks
We assess ImmunoGen's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. ImmunoGen has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

IMU Dividends

 What is ImmunoGen's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from ImmunoGen dividends.
If you bought €2,000 of ImmunoGen shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate ImmunoGen's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate ImmunoGen's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:IMU Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:IMU Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-05

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as ImmunoGen has not reported any payouts.
  • Unable to verify if ImmunoGen's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of ImmunoGen's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as ImmunoGen has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess ImmunoGen's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can ImmunoGen afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. ImmunoGen has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

IMU Management

 What is the CEO of ImmunoGen's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mark Enyedy
COMPENSATION $8,823,242
AGE 55
TENURE AS CEO 3.9 years
CEO Bio

Mr. Mark J. Enyedy has been the Chief Executive Officer and President at ImmunoGen, Inc. since May 16, 2016 and had been its Interim Principal Financial Officer since November 26, 2018. Mr. Enyedy is a Director of LogicBio Therapeutics, Inc. since March 17, 2020. He has few years of combined general management, business development and legal experience in the biotechnology industry across multiple therapeutic areas. He served as Head of Corporate Development at Shire plc since January 1, 2015 to until May 13, 2016 and served as its Company Secretary and Executive Vice President. He joined Shire in 2013 and served as its Internal Medicine Business Unit Head from August 2013 to April 2014. Mr. Enyedy served as the Interim General Counsel of Shire plc from January 1, 2015 to June 15, 2015 and led its Strategy, M&A and Corporate Planning functions and provided commercial oversight for its pre-Phase 3 portfolio. He served as the Chief Executive Officer of Proteostasis Therapeutics, Inc from 2011 to 2013. He joined Proteostasis after serving few years at Genzyme Corporation. He began his career at Genzyme Corporation in 1996 as Corporate Counsel, where he was responsible for overseeing corporate collaborations, merger and acquisition activities, financings and securities law compliance. During his tenure at Genzyme, Mr. Enyedy developed and executed its strategy to enter the oncology market and oversaw the launch of two new products and managing a global business generating over $675 million in revenue with operations in more than 50 countries. He served as the President of Transplant, Oncology & multiple sclerosis divisions and Senior Vice President at Genzyme Corporation. Mr. Enyedy served as President for Genzyme Oncology, Inc. Mr. Enyedy served as Senior Vice President and General Manager of Genzyme Molecular Oncology at Genzyme Corporation since July 16, 2003. He served as Vice President of Business Development for Genzyme Corporation, where he completed over twenty transactions, including Purdue Pharma L.P. He provided senior level transactional support for Genzyme Corporation’s other therapeutic franchises. Mr. Enyedy served as the Director of Business Development in Genzyme’s Oncology Division. He served as Vice President of Business Development at Vertex Pharmaceuticals Incorporated since February 3, 2003. He oversaw Vertex’s business development organization at its Cambridge, MA, Headquarters. From 1990 to 1996, he worked as an Associate in the business law department at Palmer & Dodge, LLP, where he represented biopharmaceutical companies in acquisition, Partnering and financing transactions. He is a Director of Akebia Therapeutics, Inc. since December 12, 2018. He was an Independent Director at Keryx Biopharmaceuticals, Inc. since September 13, 2017 until December 12, 2018. He has been a Director of ImmunoGen, Inc. since May 16, 2016. He was a Director of Fate Therapeutics, Inc. since July 2012 until May 2, 2018. He served as a Director of Proteostasis Therapeutics, Inc. Mr. Enyedy holds a BS in criminal justice from Northeastern University and a J.D. from Harvard Law School.

CEO Compensation
  • Mark's compensation has increased whilst company is loss making.
  • Mark's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the ImmunoGen management team in years:

3.9
Average Tenure
56.5
Average Age
  • The tenure for the ImmunoGen management team is about average.
Management Team

Mark Enyedy

TITLE
President
COMPENSATION
$9M
AGE
55
TENURE
3.9 yrs

David Foster

TITLE
VP of Finance & Chief Accounting Officer

Thomas Ryll

TITLE
Senior Vice President of Technical Operations
AGE
58

Courtney O’Konek

TITLE
Senior Director of Corporate Communications & Investor Relations

Audrey Bergan

TITLE
VP & Chief Human Resources Officer
TENURE
1.8 yrs

Theresa Wingrove

TITLE
Senior Vice President of Regulatory Affairs & Quality
AGE
61

Anna Berkenblit

TITLE
Senior VP & Chief Medical Officer
COMPENSATION
$999K
AGE
49
TENURE
5 yrs
Board of Directors Tenure

Average tenure and age of the ImmunoGen board of directors in years:

8.3
Average Tenure
63
Average Age
  • The tenure for the ImmunoGen board of directors is about average.
Board of Directors

Stephen McCluski

TITLE
Independent Chairman
COMPENSATION
$267K
AGE
67
TENURE
10.4 yrs

Mark Enyedy

TITLE
President
COMPENSATION
$9M
AGE
55
TENURE
3.9 yrs

Kris Peterson

TITLE
Independent Director
COMPENSATION
$237K
AGE
60
TENURE
8.3 yrs

Dean Mitchell

TITLE
Independent Director
COMPENSATION
$231K
AGE
63
TENURE
8.3 yrs

Richard Wallace

TITLE
Independent Director
COMPENSATION
$234K
AGE
68
TENURE
12.4 yrs

Mark Goldberg

TITLE
Independent Director
COMPENSATION
$227K
AGE
65
TENURE
8.4 yrs

Stuart Arbuckle

TITLE
Independent Director
COMPENSATION
$428K
AGE
53
TENURE
2.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess ImmunoGen's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. ImmunoGen has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

IMU News

Simply Wall St News

IMU Company Info

Description

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. ImmunoGen, Inc. has collaborations with Roche, Amgen/Oxford BioTherapeutics, sanofi-aventis U. S. LLC, Biotest AG, Bayer HealthCare AG, Novartis Institutes for BioMedical Research, Inc., CytomX Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Fusion Pharmaceuticals Inc., Debiopharm International SA, Jazz Pharmaceuticals Ireland Limited, and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

Details
Name: ImmunoGen, Inc.
IMU
Exchange: DB
Founded: 1980
$552,597,021
174,320,937
Website: http://www.immunogen.com
Address: ImmunoGen, Inc.
830 Winter Street,
Waltham,
Massachusetts, 02451,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS IMGN Common Stock Nasdaq Global Select US USD 17. Nov 1989
DB IMU Common Stock Deutsche Boerse AG DE EUR 17. Nov 1989
XTRA IMU Common Stock XETRA Trading Platform DE EUR 17. Nov 1989
BRSE IMU Common Stock Berne Stock Exchange CH CHF 17. Nov 1989
BMV IMGN * Common Stock Bolsa Mexicana de Valores MX MXN 17. Nov 1989
Number of employees
Current staff
Staff numbers
75
ImmunoGen employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/05 22:18
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/03/25
Last earnings filing: 2020/03/11
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.